Idiopathic pulmonary fibrosis<unk>  is used for the treatment of idiopathic pulmonary fibrosis. It has been shown to slow down decrease in forced vital capacity, and it also improves people's quality of life.<unk>  does not improve survival in people with IPF. It interferes with processes like fibroblast proliferation, differentiation and laying down extracellular matrix. The National Institute for Health and Care Excellence (NICE) recommends<unk>  in cases of IPF where the FVC is 50-80% of predicted. NICE recommends discontinuation of therapy if a person's FVC decreases by 10% or more in a 12-month period, indicating disease progression despite treatment. Lung cancer It is also used in combination with docetaxel as a second-line treatment for adult patients with locally advanced, metastatic, or locally recurring non-small cell lung cancer of adenocarcinoma histology. It is unclear how this combination compares to other second line agents as the comparisons have not been done as of 2014.
Nintedanib
Vatalanib
Gilteritinib
Abrocitinib
Pegaptanib
Tivozanib
Alectinib
Sunitinib